130 related articles for article (PubMed ID: 11603525)
1. Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits.
Little DG; Cornell MS; Briody J; Cowell CT; Arbuckle S; Cooke-Yarborough CM
J Bone Joint Surg Br; 2001 Sep; 83(7):1069-74. PubMed ID: 11603525
[TBL] [Abstract][Full Text] [Related]
2. Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis.
Little DG; Cornell MS; Hile MS; Briody J; Cowell CT; Bilston L
Injury; 2001 Dec; 32 Suppl 4():SD14-20. PubMed ID: 11812473
[TBL] [Abstract][Full Text] [Related]
3. Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis.
Pampu AA; Dolanmaz D; Tüz HH; Karabacakoglu A
J Oral Maxillofac Surg; 2006 Aug; 64(8):1232-6. PubMed ID: 16860215
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate rescue in distraction osteogenesis: a case series.
Kiely P; Ward K; Bellemore C M; Briody J; Cowell CT; Little DG
J Pediatr Orthop; 2007 Jun; 27(4):467-71. PubMed ID: 17513972
[TBL] [Abstract][Full Text] [Related]
5. The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: an animal model study.
Saghieh S; Khoury NJ; Tawil A; Masrouha KZ; Musallam KM; Khalaf K; Dosh L; Jaouhari RR; Birjawi G; El-Hajj-Fuleihan G
Bone; 2010 Feb; 46(2):363-8. PubMed ID: 19837196
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison.
Williams PR; Smith NC; Cooke-Yarborough C; Little DG
Pharmacol Toxicol; 2001 Sep; 89(3):149-52. PubMed ID: 11589787
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis.
Little DG; Smith NC; Williams PR; Briody JN; Bilston LE; Smith EJ; Gardiner EM; Cowell CT
J Bone Miner Res; 2003 Jul; 18(7):1300-7. PubMed ID: 12854841
[TBL] [Abstract][Full Text] [Related]
8. [Cyclic intravenous pamidronate in treatment of osteoporosis].
Vujasinović-Stupar N; Pilipović N; Branković S
Med Pregl; 2004; 57(11-12):545-50. PubMed ID: 16107000
[TBL] [Abstract][Full Text] [Related]
9. Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits.
Pampu AA; Dolanmaz D; Tüz HH; Avunduk MC; Kişnişci RS
J Oral Maxillofac Surg; 2008 May; 66(5):905-10. PubMed ID: 18423279
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
11. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Vis M; Bultink IE; Dijkmans BA; Lems WF
Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
[TBL] [Abstract][Full Text] [Related]
12. Optimal increase in bone mass by continuous local infusion of alendronate during distraction osteogenesis in rabbits.
Abbaspour A; Takahashi M; Sairyo K; Takata S; Yukata K; Inui A; Yasui N
Bone; 2009 May; 44(5):917-23. PubMed ID: 19442623
[TBL] [Abstract][Full Text] [Related]
13. Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Bayram F; Tanriverdi F; Kurtoğlu S; Atabek ME; Kula M; Kaynar L; Keleştimur F
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):275-9. PubMed ID: 16607930
[TBL] [Abstract][Full Text] [Related]
14. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
15. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.
Lee YS; Low SL; Lim LA; Loke KY
Eur J Pediatr; 2001 Nov; 160(11):641-4. PubMed ID: 11760017
[TBL] [Abstract][Full Text] [Related]
16. Demineralized Bone Matrix Injection in Consolidation Phase Enhances Bone Regeneration in Distraction Osteogenesis via Endochondral Bone Formation.
Kim JB; Lee DY; Seo SG; Kim EJ; Kim JH; Yoo WJ; Cho TJ; Choi IH
Clin Orthop Surg; 2015 Sep; 7(3):383-91. PubMed ID: 26330963
[TBL] [Abstract][Full Text] [Related]
17. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
Cauza E; Etemad M; Winkler F; Hanusch-Enserer U; Partsch G; Noske H; Dunky A
J Clin Pharm Ther; 2004 Oct; 29(5):431-6. PubMed ID: 15482386
[TBL] [Abstract][Full Text] [Related]
19. Acceleration of regenerate ossification during distraction osteogenesis with recombinant human bone morphogenetic protein-7.
Mizumoto Y; Moseley T; Drews M; Cooper VN; Reddi AH
J Bone Joint Surg Am; 2003; 85-A Suppl 3():124-30. PubMed ID: 12925619
[TBL] [Abstract][Full Text] [Related]
20. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.
Gallacher SJ; Fenner JA; Anderson K; Bryden FM; Banham SW; Logue FC; Cowan RA; Boyle IT
Thorax; 1992 Nov; 47(11):932-6. PubMed ID: 1465751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
